Verastem, Inc. · NASDAQ:VSTM

Verastem — The 68th Annual Meeting of Japan Society of Gynecologic Oncology 2026

14 slides from Verastem's conference presentation, Jul 17, 2026

  1. Slide 1: A Phase 2 Trial of Avutometinib and Defactinib in Japanese Patients With Recurrent LGSOC

    A Phase 2 Trial of the Combination Therapy of Avutometinib and Defactinib in Japanese Patients With Recurrent Low-Grade Serous Ovarian Cancer Michiko Kaneda1, Muneaki Shimada2, Takafumi Kuroda3, Shin Nishio4, Shiro Suzuki5, Shogo Shigeta6, Ryosuke Saito3, Tadaaki Nishikawa3, Eiji Kondo1, Vijeta Bham

  2. Slide 2: Low-Grade Serous Ovarian Cancer

    Low-Grade Serous Ovarian Cancer Mutations in patients with LGSOC3,4,7,8 ▪ Low-grade serous ovarian cancer (LGSOC) is a rare, histopathologic, molecular, and clinically distinct cancer subtype accounting for <10% of NRAS, BRAF, and ARAF mt new epithelial ovarian cancers1,2 KRAS mt 20% 30% ▪ LGSOC is

  3. Slide 3: Avutometinib + Defactinib Mechanism of Action

    Avutometinib + Defactinib Mechanism of Action Avutometinib + defactinib mechanism of action Vertical blockade Parallel blockade Growth factors Extracellular matrix ▪ Avutometinib is a RAF/MEK clamp that potently inhibits MEK while also blocking the compensatory reactivation of MEK by upstream RAF1,2

  4. Slide 4: Avutometinib + Defactinib Clinical Data in Patients With Recurrent LGSOC

    Avutometinib + Defactinib Clinical Data in Patients With Recurrent LGSOC ▪ Avutometinib + defactinib combination therapy was approved by the FDA for treatment the of patients with recurrent KRAS-mutated LGSOC based on the RAMP 201 single-arm international trial conducted in the US, Europe, and Canad

  5. Slide 5: RAMP 201J Study Design

    RAMP 201J Study Design Avutometinib 3.2 mg BIW + Defactinib 200 mg BID ▪ This phase 2 study (RAMP 201J) is designed to evaluate the efficacy, pharmacokinetics, and safety of avutometinib + defactinib in Japanese patients with recurrent LGSOC ▪ Patients with recurrent LGSOC (KRAS mt or wt) who progre

  6. Slide 6: Patient Baseline Characteristics

    All patients Characteristic Patient Baseline Characteristics (N=16) Age, median (range), y 47 (23-72) Avutometinib 3.2 mg BIW + Defactinib 200 mg BID ECOG PS, n (%) 0 14 (88) 1 2 (13) ▪ At data cutoff, 16 patients were enrolled KRAS status, n (%) 7 (44) KRAS mt 7 patients with KRAS mt tumors 9 (56)

  7. Slide 7: Patient Disposition

    Patient Disposition Avutometinib 3.2 mg BIW + Defactinib 200 mg BID At the time of data cutoff, the median (range) duration of follow-up was 12.4 (5.4-18.1) mo All patients Patient disposition, n (%) (N=16) Patients treated 16 (100)  Of the 16 patients enrolled, Patients on treatment at data cutoff

  8. Slide 8: ORR and Best Percent Change in Target Lesions and Response

    ORR and Best Percent Change in Target Lesions and Response (by Investigator Assessment) Avutometinib 3.2 mg BIW + Defactinib 200 mg BID 20 KRAS mt KRAS wt All patients 8 Response rates, n (%) * * * * * * * * * * * (n=7) (n=9) (N=16) SD SD SD SD SD SD SD SD PR PR PR PR PR PR PR 0 Best Percent Change

  9. Slide 9: Duration of Treatment (by Investigator Assessment)

    Duration of Treatment (by Investigator Assessment) Avutometinib 3.2 mg BIW + Defactinib 200 mg BID 1402-003 SD PR * 1402-001 SD * 1402-002 SD * 1402-004 SD PR * 1404-001 SD PR *  44% (7/16) of patients 1402-006 SD PR * received treatment for >12 mo 1405-002 SD * SD PR * Patients 1401-004  Median (

  10. Slide 10: Disease Control in Avutometinib + Defactinib in Patients With KRAS mt and KRAS wt LGSOC

    Disease Control in Avutometinib + Defactinib in Patients With KRAS mt and KRAS wt LGSOC Avutometinib 3.2 mg BIW + Defactinib 200 mg BID KRAS mt KRAS wt (n=7) (n=9) 80 80 60 60 Percent Change in Target Lesion Percent Change in Target Lesion 40 40 Prolonged Sum of Diameters, % Sum of Diameters, % 20 2

  11. Slide 11: Pharmacokinetics of Avutometinib and Defactinib in RAMP 201J and RAMP 201

    Pharmacokinetics of Avutometinib and Defactinib in RAMP 201J and RAMP 201 Avutometinib 3.2 mg BIW + Defactinib 200 mg BID Avutometinib Avutometinib Defactinib (n=15) C1D15 (n=14) C1D15 C1D15 1500 8000 6000 The pharmacokinetic 1000 profile was similar between 4000 patients in RAMP 201J and RAMP 201,

  12. Slide 12: Safety Profile: No New Safety Signals Observed

    Safety Profile: No New Safety Signals Observed All patients Treatment-related AEs, a n (%) (N=16) Avutometinib 3.2 mg BIW + Defactinib 200 mg BID Preferred term All grades Grade 3b Any treatment-related AE 16 (100) 9 (56) Treatment-related AEs (≥25% of patients) Nonlaboratory AEs ▪ Most treatment-re

  13. Slide 13: Efficacy, Pharmacokinetic, and Safety Profiles Comparable to the Larger International RAMP 201 Study

    Efficacy, Pharmacokinetic, and Safety Profiles of Avutometinib + Defactinib in Japanese Patients are Comparable to the Larger International RAMP 201 Study ▪ Avutometinib + defactinib (median follow-up, 12.4 mo) demonstrated promising preliminary efficacy in Japanese patients with recurrent LGSOC  O

  14. Slide 14: Acknowledgements

    Acknowledgements We thank the patients and their families for their participation and the trial teams at participating centers for their support of this study. This study is sponsored by Verastem Oncology. The 68th Annual Meeting of Japan Society of Gynecologic Oncology | July 17-19, 2026 | Sapporo,

Verastem — The 68th Annual Meeting of Japan Society of Gynecologic Oncology 2026 on 6ix